Suppr超能文献

NKT TCR 识别 CD1d-α-半乳糖神经酰胺。

NKT TCR recognition of CD1d-α-C-galactosylceramide.

机构信息

Australian Research Council Centre of Excellence in Structural and Functional Microbial Genomics, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia.

出版信息

J Immunol. 2011 Nov 1;187(9):4705-13. doi: 10.4049/jimmunol.1100794. Epub 2011 Sep 30.

Abstract

NKT cells respond to a variety of CD1d-restricted glycolipid Ags that are structurally related to the prototypic Ag α-galactosylceramide (α-GalCer). A modified analog of α-GalCer with a carbon-based glycosidic linkage (α-C-GalCer) has generated great interest because of its apparent ability to promote prolonged, Th1-biased immune responses. In this study, we report the activation of spleen NKT cells to α-C-GalCer, and related C-glycoside ligands, is weaker than that of α-GalCer. Furthermore, the Vβ8.2 and Vβ7 NKT TCR affinity for CD1d-α-C-GalCer, and some related analogs, is ∼10-fold lower than that for the NKT TCR-CD1d-α-GalCer interaction. Nevertheless, the crystal structure of the Vβ8.2 NKT TCR-CD1d-α-C-GalCer complex is similar to that of the corresponding NKT TCR-CD1d-α-GalCer complex, although subtle differences at the interface provide a basis for understanding the lower affinity of the NKT TCR-CD1d-α-C-GalCer interaction. Our findings support the concept that for CD1d-restricted NKT cells, altered glycolipid ligands can promote markedly different responses while adopting similar TCR-docking topologies.

摘要

NKT 细胞对各种与原型抗原 α-半乳糖神经酰胺(α-GalCer)结构相关的 CD1d 限制型糖脂抗原作出反应。具有碳糖苷键的 α-GalCer 的一种改良类似物(α-C-GalCer)由于其明显能够促进延长的、偏向 Th1 的免疫反应而引起了极大的兴趣。在这项研究中,我们报告了 α-C-GalCer 以及相关的 C-糖苷配体对脾 NKT 细胞的激活作用弱于 α-GalCer。此外,Vβ8.2 和 Vβ7 NKT TCR 对 CD1d-α-C-GalCer 的亲和力,以及一些相关的类似物,比 NKT TCR-CD1d-α-GalCer 相互作用的亲和力低约 10 倍。然而,Vβ8.2 NKT TCR-CD1d-α-C-GalCer 复合物的晶体结构与相应的 NKT TCR-CD1d-α-GalCer 复合物相似,尽管在界面处存在细微差异为理解 NKT TCR-CD1d-α-C-GalCer 相互作用的低亲和力提供了基础。我们的发现支持这样的概念,即对于 CD1d 限制的 NKT 细胞,改变的糖脂配体可以在采用相似的 TCR 对接拓扑结构的同时促进明显不同的反应。

相似文献

1
NKT TCR recognition of CD1d-α-C-galactosylceramide.
J Immunol. 2011 Nov 1;187(9):4705-13. doi: 10.4049/jimmunol.1100794. Epub 2011 Sep 30.
2
Human and mouse type I natural killer T cell antigen receptors exhibit different fine specificities for CD1d-antigen complex.
J Biol Chem. 2012 Nov 9;287(46):39139-48. doi: 10.1074/jbc.M112.412320. Epub 2012 Sep 20.
3
Atypical natural killer T-cell receptor recognition of CD1d-lipid antigens.
Nat Commun. 2016 Feb 15;7:10570. doi: 10.1038/ncomms10570.
5
Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
Scand J Immunol. 2019 Sep;90(3):e12794. doi: 10.1111/sji.12794. Epub 2019 Jun 26.
8
Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
J Mol Biol. 2009 Nov 20;394(1):71-82. doi: 10.1016/j.jmb.2009.08.061. Epub 2009 Sep 2.
10
The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex.
J Immunol. 2002 Aug 1;169(3):1340-8. doi: 10.4049/jimmunol.169.3.1340.

引用本文的文献

1
State of play in the molecular presentation and recognition of anti-tumor lipid-based analogues.
Front Immunol. 2024 Nov 28;15:1479382. doi: 10.3389/fimmu.2024.1479382. eCollection 2024.
2
Early infiltrating NKT lymphocytes attenuate bone regeneration through secretion of CXCL2.
Sci Adv. 2024 May 17;10(20):eadl6343. doi: 10.1126/sciadv.adl6343.
3
Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients.
Cell Rep Med. 2023 Oct 17;4(10):101241. doi: 10.1016/j.xcrm.2023.101241.
4
CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy.
Cancer Cell Int. 2023 May 8;23(1):86. doi: 10.1186/s12935-023-02923-9.
5
Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates.
Front Immunol. 2022 Mar 30;13:852147. doi: 10.3389/fimmu.2022.852147. eCollection 2022.
6
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead.
Cancers (Basel). 2021 Oct 15;13(20):5174. doi: 10.3390/cancers13205174.
7
Immunomodulatory properties of characellide A on human peripheral blood mononuclear cells.
Inflammopharmacology. 2021 Aug;29(4):1201-1210. doi: 10.1007/s10787-021-00836-5. Epub 2021 Jul 9.
9
Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment.
Acta Pharm Sin B. 2020 Nov;10(11):2110-2124. doi: 10.1016/j.apsb.2020.05.008. Epub 2020 May 31.

本文引用的文献

2
Galacto-configured aminocyclitol phytoceramides are potent in vivo invariant natural killer T cell stimulators.
J Am Chem Soc. 2011 Aug 10;133(31):12079-84. doi: 10.1021/ja202610x. Epub 2011 Jul 20.
4
New ways to turn on NKT cells.
J Exp Med. 2011 Jun 6;208(6):1121-5. doi: 10.1084/jem.20110983.
5
Invariant NKT cells are required for airway inflammation induced by environmental antigens.
J Exp Med. 2011 Jun 6;208(6):1151-62. doi: 10.1084/jem.20102229. Epub 2011 May 30.
7
Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis.
EMBO J. 2011 Jun 1;30(11):2294-305. doi: 10.1038/emboj.2011.145. Epub 2011 May 6.
8
The stimulating adventure of KRN 7000.
Org Biomol Chem. 2011 May 7;9(9):3080-104. doi: 10.1039/c0ob00975j. Epub 2011 Mar 11.
9
A molecular basis for NKT cell recognition of CD1d-self-antigen.
Immunity. 2011 Mar 25;34(3):315-26. doi: 10.1016/j.immuni.2011.01.013. Epub 2011 Mar 3.
10
A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells.
Immunity. 2011 Mar 25;34(3):327-39. doi: 10.1016/j.immuni.2011.02.001. Epub 2011 Mar 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验